Virtual reality for management of pain in hospitalized patients: A randomized comparative effectiveness trial

Brennan Spiegel, Garth Fuller, Mayra Lopez, +15

PLoS ONE

Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study

B. Guess, Mark C. Scholz, Stephen B. Strum, +3

Prostate Cancer and Prostatic Diseases

UrologyGenitourinary CancerMedicinePathologyModified Citrus Pectin +3

Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer

Mark C. Scholz, Sabrina Yep, Micah Chancey, +5

ImmunoTargets and Therapy

LONG-TERM OUTCOME FOR MEN WITH ANDROGEN INDEPENDENT PROSTATE CANCER TREATED WITH KETOCONAZOLE AND HYDROCORTISONE

Mark C. Scholz, Robert I. Jennrich, Stephen B. Strum, +3

The Journal of Urology

Depletion of SAM leading to loss of heterochromatin drives muscle stem cell ageing

Jengmin Kang, Daniel I. Benjamin, Soochi Kim, +7

Nature Metabolism

ChromatinChromatin StructureCell SpecializationHeterochromatin DrivesMedicine +10

Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period

Mark C. Scholz, Robert I. Jennrich, Stephen B. Strum, +3

The Journal of Urology

Older adult consumers' attitudes and preferences on electronic patient-physician messaging.

Richard Y. Lam, Victor S. Lin, Wnedy S Senelick, +3

PubMed

Structure-Based Design and Synthesis of Potent and Selective KRAS G12D Inhibitors

Hengmiao Cheng, Puhui Li, Ping Chen, +13

ACS Medicinal Chemistry Letters

Survival after sipuleucel-T (SIP-T) and low-dose ipilimumab (IPI) in men with metastatic, progressive, castrate-resistant prostate cancer (M-CRPC).

Justine Ku, Kirk Wilenius, Claire Larsen, +5

Journal of Clinical Oncology

Cancer ManagementImmunologyCastrate-resistant Prostate CancerPharmacotherapyImmunotherapeutics +18

Prostate Cancer-Specific Survival and Clinical Progression-Free Survival in Men with Prostate Cancer Treated Intermittently with Testosterone Inactivating Pharmaceuticals

Mark C. Scholz, Richard Y. Lam, Stephen B. Strum, +3

Urology

Clinical Progression-free SurvivalUrologyOncologyGenitourinary CancerCancer Management +4